Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib and Pembrolizumab in advanced melanoma
NCT03820986Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2019
- Primary completion
- Jan 2023
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial of lenvatinib in Malignant Melanoma (MM), sponsored by Merck & Co. Primary endpoints: Progression-Free Survival at 34 months and Overall Survival at 46 months. Started Mar 2019; status: completed.
02
Drugs
lenvatinib
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT03820986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03820986.